Health Conditions

Colitis

Other NamesAcute colitis

Natural Remedies10

Ingredients101

Table of contents

Other Names

Acute colitisAcute self-limited colitisAllergic colitisAutoimmune enterocolitisC-diff colitisC. difficile colitisChemical colitisChemotherapy-induced colitisChronic colitisClostridioides difficile colitisCollagenous colitisCollagenous colitis incomplete (CCi)Colon inflammationColonitisCorrosive colitisCrohn colitisCrohn's disease (colitis type)Disinfectant colitisDisuse colitisDiversion colitisDrug-induced colitisEnterocolitisEosinophilic colitisFocal active colitisFulminant colitisIdiopathic colitisIdiopathic ulcerative colitisIleocolitisImmune checkpoint inhibitor colitisInfectious colitisInflammation of the colonInflammatory bowel disease (IBD)Ischemic colitisLarge intestine inflammationLymphocytic colitisLymphocytic colitis incomplete (LCi)Microscopic colitisMicroscopic colitis incomplete (MCi)Minimal change colitisMucous colitisNecrotizing enterocolitisNeutropenic enterocolitisPouchitisProctocolitisPseudomembranous colitisRadiation colitisRadiation-induced colitisSegmental colitis associated with diverticulosisSpastic colitisUlcerative colitis

Synopsis

Colitis: A Nutrition and Natural Health Reference

1. Definition and Overview

Colitis is inflammation of the mucosal lining of the colon, which may be acute or chronic. It is common and increasing in prevalence worldwide. The term encompasses a heterogeneous group of disorders unified by the presence of colonic inflammation but differing substantially in their underlying mechanisms, clinical trajectories, and natural histories.

Colitis has different types and results from several mechanisms including infection, autoimmunity, ischemia, and drugs. It may also occur secondary to immune deficiency disorders or secondary to exposure to radiation.

2. Major Clinical Types

2.1 Ulcerative Colitis (UC)

Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide. The pathogenesis is multifactorial, involving genetic predisposition, epithelial barrier defects, dysregulated immune responses, and environmental factors.

Patients with ulcerative colitis have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. Ulcerative colitis usually presents with bloody diarrhoea and is diagnosed by colonoscopy and histological findings.

Ulcers form in places where the inflammation has killed the cells lining the colon; the ulcers bleed and produce pus. It is characterised by relapsing and remitting mucosal inflammation, starting in the rectum and extending to proximal segments of the colon. Ulcerative colitis most commonly afflicts adults aged 30–40 years and results in disability.

Ulcerative colitis affects men and women equally and appears to run in some families. Ulcerative colitis may occur in people of any age, but most often it starts between ages 15 and 30, or less frequently between ages 50 and 70.

2.2 Crohn's Disease Colitis

Ulcerative colitis is characterized by inflammation and ulceration confined to colonic mucosa, whereas Crohn's disease is manifested by transmural inflammation and granulomas that may affect any segment of the GI tract, including the colon. Crohn's disease usually occurs in the small intestine, although it can also occur in the mouth, esophagus, stomach, duodenum, large intestine, appendix, and anus.

2.3 Microscopic Colitis

Microscopic colitis (MC) is an inflammatory bowel disease and a common cause of chronic, watery, and non-bloody diarrhoea. It is diagnosed histologically rather than endoscopically. Two primary subtypes are recognized:

Collagenous colitis: defined by a collagen band greater than 10 micrometers in diameter in the subepithelial layer.
Lymphocytic colitis: defined by twenty or more intraepithelial lymphocytes per 100 epithelial cells, typically without crypt distortion.

A typical patient with microscopic colitis presents with non-bloody, watery diarrhea that has been present for some time. As this condition definitively presents with chronic diarrhea, symptoms should be present with that definition, which is 3 or more loose or watery stools daily lasting more than 4 weeks. The incidence has been increasing throughout northern Europe and northern North America, and it is more common in women.

3. Clinical Presentation and Symptoms

Patients with colitis present with watery diarrhea, abdominal pain, tenesmus, urgency, fever, tiredness, and blood in the stool. Symptom severity ranges considerably across individuals and subtypes.

The inflammation makes the colon empty frequently, causing diarrhea. The most common symptoms of ulcerative colitis are abdominal pain and bloody diarrhea. Patients also may experience fatigue, weight loss, loss of appetite, rectal bleeding, and loss of body fluids and nutrients. About half of patients have mild symptoms. Others suffer frequent fever, bloody diarrhea, nausea, and severe abdominal cramps.

3.1 Extraintestinal Manifestations

Ulcerative colitis may also cause problems such as arthritis, inflammation of the eye, liver disease (hepatitis, cirrhosis, and primary sclerosing cholangitis), osteoporosis, skin rashes, and anemia. Scientists think these complications may occur when the immune system triggers inflammation in other parts of the body. In some patients, extraintestinal manifestations may predate the onset of gastrointestinal symptoms.

4. Body Systems Involved

Colitis, particularly ulcerative colitis and Crohn's colitis, is not simply a gastrointestinal disease; it involves multiple organ systems:

Gastrointestinal system: The primary site. The pathogenesis involves genetic predisposition, epithelial barrier defects, dysregulated immune responses, and environmental factors.
Immune system: The most popular theory is that the body's immune system reacts to a virus or a bacterium by causing ongoing inflammation in the intestinal wall. People with ulcerative colitis have abnormalities of the immune system, but doctors do not know whether these abnormalities are a cause or a result of the disease.
Gut microbiome: Dysbiosis of the intestinal microbiota is recognized as a major factor contributing to various forms of colitis.
Musculoskeletal system: Arthritis and osteoporosis are recognized extraintestinal manifestations.
Hepatobiliary system: Liver disease, including primary sclerosing cholangitis, is a known complication.
Integumentary and ophthalmologic systems: Skin rashes and ocular inflammation are documented extraintestinal features.

5. Contributing and Associated Factors

5.1 Genetics

The pathogenesis of IBD involves complex interactions between genetic predisposition (e.g., NOD2 polymorphisms) and environmental triggers (e.g., diet and antibiotics). Emerging evidence suggests that gut microbiota dysbiosis serves as a unifying mechanism bridging these risk factors. The key mechanism underlying the pathogenesis of these diseases is a dysregulated immune response to commensal flora in a genetically susceptible host. Thus intestinal microbial dysbiosis, host genetics, and the external environment all play an important role in the development of incident disease and in determining subsequent disease behavior and outcomes.

5.2 Gut Microbiome Dysbiosis

The human gut microbiota fosters a symbiotic relationship with its host. In a state of health, the intestinal microbiota fulfills numerous vital physiological roles within the host, such as the digestion and metabolic processing of non-absorbable dietary components, the synthesis of essential vitamins, the modulation of the epithelial barrier, and the maturation of the intestinal immune system.

The mechanisms by which microbiota alterations contribute to colitis pathogenesis predominantly involve disruption of barrier function, aberrant immune responses, and damage induced by microbial metabolites.

The dysbiosis of microbes is characterized by reduced biodiversity, abnormal composition of gut microbiota, altered spatial distribution, as well as interactions among microbiota, between different strains of microbiota, and with the host. A significant decrease in beneficial intestinal bacteria (Bifidobacterium longum, Eubacterium rectale, Faecalibacterium prausnitzii, Roseburia intestinalis), as well as enrichment in several harmful bacteria, is connected to intestinal inflammation.

For microscopic colitis specifically, several studies have shown reduced alpha diversity as well as a rise in the dysbiosis index in active microscopic colitis, with loss of beneficial taxa as well as enrichment of oral-associated, inflammatory bacteria. Research illustrates reduced alpha diversity, high dysbiosis, and pro-inflammatory oral-associated taxa enrichment, such as Veillonella dispar, and loss of protective microbes such as Akkermansia muciniphila and Bacteroides stercoris.

5.3 Diet

A Western diet, high in animal protein, processed foods, and low in fiber, is associated with the development of UC and CD. Epidemiologic studies also identify that a diet high in a ratio of n-6 to n-3 polyunsaturated fatty acids increases UC risk.

Human studies have shown that high consumption of fats, especially those derived from animal sources, and cholesterol is significantly associated with an increased risk of UC.

5.4 Smoking

The relationship between tobacco smoking and colitis is complex and varies by disease type. Current smoking increases the risk of developing Crohn's disease and worsens its course, increasing the need for steroids, immunosuppressants, and re-operations. On the contrary, smoking protects against ulcerative colitis and after disease onset improves its course, decreasing the need for colectomy. Smoking cessation improves Crohn's disease and worsens ulcerative colitis.

Since the first described inverse association between UC and smoking in 1982, subsequent studies confirmed the protective effect of current smoking on the development of UC, lower rate of relapse, and reduced need for colectomy in current smokers. Current smoking is associated with an increased risk of Crohn's disease, but not UC. By contrast, former smoking is associated with an increased risk of UC, with risk persisting over two decades after cessation.

In microscopic colitis, the direction differs again: smoking is a risk factor for collagenous colitis, whereas its impact on clinical activity and outcome is not well known.

5.5 Environmental and Lifestyle Triggers

There are several well-defined or putative environmental risk factors including cigarette smoking, appendectomy, diet, stress and depression, vitamin D, as well as hormonal influence.

Countries that have witnessed a rapidly changing environment and lifestyle have seen an increase in the incidence of IBD over the past few decades at a rate of change that outpaces what could be attributed solely to genetics.

Physical activity improves quality of life without detrimental effect on disease activity, and may contribute to increase muscle mass and to prevent osteoporosis.

5.6 Medications as a Contributing Factor

There have been two possible causes of microscopic colitis theorized, including a genetic component that predisposes to the condition, including medications and smoking tobacco. Discontinuation of the offending agent often induces clinical remission in drug-induced colitis.

6. Nutritional Status and Deficiencies in Colitis

6.1 Vitamin D

Vitamin D deficiency is common in inflammatory bowel disease (IBD). IBD is significantly associated with having higher odds of vitamin D deficiency.

Vitamin D has recently been discovered to be a potential immune modulator. Low serum vitamin D levels have been associated with risk of relapse and exacerbation of clinical outcomes in Crohn's disease and ulcerative colitis.

Serum 25(OH)D₃ was inversely correlated with faecal calprotectin for CD and UC but was only correlated with C-reactive protein for UC patients. A deficiency of 25(OH)D₃ was associated with increased hospitalisations, flare-ups, the use of steroids, and escalating treatment.

In one retrospective cohort of 504 IBD patients, 49.8% were vitamin D deficient, with 10.9% having severe deficiency.

Vitamin D in its active form, 1,25-dihydroxyvitamin D₃, plays a critical role in immune regulation, gut barrier function, and systemic inflammation. Vitamin D deficiency is common among IBD patients and independently associates with systemic inflammation, metabolic impairment, and intensified treatment requirement, supporting its potential role as a marker of disease burden.

6.2 Other Nutritional Concerns

Chronic inflammation, diarrhea, and malabsorption predispose patients with colitis to broad-spectrum nutritional inadequacies. Dietary fiber and vitamins found in fruits and vegetables assist in maintaining the intestinal mucosal barrier and balancing the intestinal inflammatory response, both of which are advantageous for people with IBD.

7. Nutrients Studied in Relation to Colitis

7.1 Omega-3 Fatty Acids (Fish Oil)

Scientific Evidence: The European Crohn's and Colitis Organization (ECCO) concluded that omega-3 fatty acids may be beneficial in maintaining remission in Crohn's disease; however, study quality and heterogeneity of trials limit these findings. Epidemiological data indicate that a diet high in a ratio of n-6 to n-3 polyunsaturated fatty acids increases UC risk. The evidence from intervention trials is considered preliminary and limited by study heterogeneity.

7.2 Vitamin D

Scientific Evidence: In a double-blind randomized clinical trial, 50 patients with mild to moderate UC who met inclusion criteria received either 1000 or 2000 IU/day of vitamin D for 12 weeks. At the end of the study, serum 25-OHD levels significantly increased in the high-dose group. However, supplemental doses of vitamin D were likely to be insufficient to reach adequate serum levels in many patients, underscoring the need for individually tailored intervention studies. Vitamin D intervention studies are warranted to determine whether giving higher doses of vitamin D in IBD might reduce intestinal inflammation or disease activity.

7.3 Dietary Fiber and Short-Chain Fatty Acids (SCFAs)

Scientific Evidence: Patients with IBD have reduced levels of SCFAs, and a Western Diet Pattern decreases protective SCFA-producing bacteria, which promotes inflammatory responses in the gut. Dietary fiber acts as the substrate for SCFA production by colonic bacteria. Dietary fiber generates SCFAs which play anti-inflammatory and barrier-supportive roles in the colon. The strength of evidence linking increased fiber intake to improved UC outcomes is considered moderate but promising, with ongoing research needed.

8. Herbs and Natural Ingredients Studied in Relation to Colitis

The use of complementary medicine among patients with ulcerative colitis, particularly in the form of herbal therapies, is widespread in the Western world and in many Asian countries including China and India.

8.1 Curcumin (Curcuma longa)

Traditional Use: Curcumin is the principal bioactive polyphenol of turmeric (Curcuma longa), a rhizomatous plant native to South Asia that has been used for millennia in Ayurvedic and traditional Chinese medicine as an anti-inflammatory and digestive remedy. Its topical and oral use for conditions involving heat, swelling, and digestive disturbance is well documented in these traditions.

Scientific Evidence: The European Crohn's and Colitis Organization (ECCO) outlined that curcumin, in combination with 5-ASA, may be effective in inducing remission in mild-to-moderate UC as well as potentially being effective as a complementary maintenance therapy in UC.

Curcumin supplementation, compared to placebo, was associated with significant improvements in clinical improvement and endoscopic improvement. Curcumin did not increase the risk of serious adverse events compared to placebo. This provides evidence for the potential use of curcumin-containing drugs as adjunctive therapies to alleviate symptoms in UC patients.

However, the overall quality of evidence must be interpreted carefully: seven published systematic reviews and meta-analyses on curcumin for UC were evaluated and, according to AMSTAR-2 assessment, all were considered to be of very low quality. According to ROBIS evaluation results, no systematic review was assessed as a low risk of bias. Curcumin may be an effective and safe complementary treatment for UC; however, further standard and comprehensive systematic reviews and RCTs are needed.

8.2 Aloe Vera (Aloe barbadensis Mill.)

Traditional Use: Aloe vera (Aloe barbadensis Mill.) belongs to the Aloeaceae family with thick, tapered, green lance-shaped, juicy leaves. It grows in dry regions of Africa, Europe, Asia, and America and is probably the most applied medicinal plant commercially and the most popular plant worldwide. Historically, its gel has been used across many cultures — including in traditional African, Middle Eastern, and Ayurvedic medicine — for soothing inflamed mucous membranes and treating diarrheal conditions.

Scientific Evidence: Although the exact mechanism of aloe is not fully understood, an in vitro study found that aloe gel reduced secretion of prostaglandin E2 and interleukin-18 (IL-18) in the colon mucosa, which suggested that the gel had anti-inflammatory and anti-microbial effects. In an in vivo study, aloe extract reduced tumor necrosis factor-α (TNF-α) levels and the expression of IL-1β mRNA, which were indicative of anti-inflammatory effects.

Aloe vera gel was well tolerated in one randomized trial, with no significant differences in adverse events between treatment and placebo groups. Further studies are required to assess the efficacy and safety of aloe vera in the management of UC. There are limited and restricted evidences indicating the efficacy of herbal medicine such as aloe vera gel in the management of patients with ulcerative colitis.

8.3 Boswellia (Boswellia serrata)

Traditional Use: Boswellia serrata is an Indian mastic tree, and the resin collected from its stem has been used in traditional medicine. It features prominently in Ayurvedic medicine under the name Shallaki, where its resin has been used for inflammatory joint conditions and digestive disorders for centuries.

Scientific Evidence: Boswellic acids, the primary bioactive compounds in Boswellia serrata, have demonstrated anti-inflammatory effects that have been studied in colitis models. There are limited controlled evidences indicating the efficacy of Boswellia serrata in the management of patients with UC. Small-scale human studies, such as one pilot study on 300 mg of boswellia resin three times daily in chronic colitis patients, suggested potential benefit, but these findings have not been robustly confirmed in larger, adequately powered randomized trials. The overall evidence base remains preliminary.

8.4 Slippery Elm (Ulmus rubra)

Traditional Use: Slippery Elm has been used traditionally to treat coughing, diarrhea, and gastrointestinal tract diseases by Native Americans. The Eclectics used slippery elm for inflammation of the lungs, bowels, stomach, bladder, or kidneys. The inner bark is rich in mucilaginous polysaccharides that are believed to coat and soothe irritated mucosal surfaces.

Scientific Evidence: The bark of Slippery Elm was suggested to be effective for treating IBD patients owing to its antioxidant effects; however, further studies are needed to confirm its efficacy. Formal clinical trial evidence in humans with colitis remains sparse, and the ingredient is classified as a traditional/empirical remedy at this time.

8.5 Other Traditionally Used Herbs

Herbal remedies reported for the treatment of IBD include slippery elm, fenugreek, devil's claw, Mexican yam, tormentil, and Wei tong ning (a traditional Chinese medicine). Tormentil (Potentilla erecta) is a perennial plant belonging to the family Rosaceae, whose roots are rich in tannins, which have anti-inflammatory effects. The evidence base for most of these is limited to small pilot studies or traditional use reports, and robust clinical trial data in humans with colitis are lacking.

9. Probiotics and the Gut Microbiome

Traditional and Historical Context: Fermented foods — including yogurt, kefir, kimchi, miso, and various cultured dairy products — have been consumed across global cultures for millennia and are among the oldest known sources of live microbial cultures used to support digestive health.

Scientific Evidence: The imbalance of gastrointestinal microbial composition has been identified as a major factor in chronic inflammatory diseases. At present, probiotics have a beneficial effect on the microbial composition of the human gastrointestinal tract, but it is still controversial and the specific mechanism is unknown.

A systematic review of randomized controlled trials in IBD found: in patients with Crohn's disease, multiple studies comparing probiotics and placebo showed no significant difference in clinical outcomes. Adding a probiotic to conventional treatment improved the overall induction of remission rates among patients with UC.

A preclinical systematic review and network meta-analysis found: L. rhamnosus has the best effect in relieving weight loss and improving the Shannon index in the ulcerative colitis model. E. faecium has the best effect in reducing colon injury; however, probiotics do not always provide benefits to patients, the effects of different strains are quite different, and the mechanism of action is also different, which is closely related to the type and stage of the disease, the strains and doses of probiotics used.

Ulcerative colitis is a chronic immune-mediated inflammatory bowel disease of unknown aetiology that affects the colon. Patients with UC typically exhibit dysbiosis — an altered gut microbiota profile compared with healthy individuals.

Overall, evidence for probiotics in UC is more promising than in Crohn's colitis, but heterogeneity across strains, dosing, and study populations limits definitive conclusions. Relevant clinical trials are currently lacking, so the extension of animal experimental findings to clinical application requires a longer period of consideration for validation.

10. Dietary Patterns and Lifestyle Factors

10.1 Western Dietary Pattern

The Western diet disturbs gut microbiota and contains pro-inflammatory potential food. The rising incidence of IBD, specifically in the developing world, suggests an important environmental effect. Amongst environmental influences, dietary factors, particularly the adoption of a westernized diet, have been specifically noticed.

10.2 Mediterranean Dietary Pattern

The Mediterranean diet, characterized by high intake of fruits, vegetables, whole grains, legumes, nuts, olive oil, and moderate consumption of animal and ultra-processed foods, has shown potential positive effects in IBD.

Epidemiological studies suggest an inverse association of the Mediterranean diet with Crohn's disease development. Furthermore, adherence to the Mediterranean diet has been associated with clinical improvement in active CD and maintenance of lower levels of inflammatory markers in UC, along with improved quality of life and lower mortality rates in IBD patients.

A prospective randomized controlled trial specifically in UC found: dietary patterns are important in managing ulcerative colitis, given their influence on gut microbiome-host symbiosis and inflammation. The Mediterranean Diet Pattern versus the Canadian Habitual Diet Pattern affected disease activity, inflammation, and the gut microbiome in patients with quiescent UC. The study followed participants for 12 weeks and measured disease activity via Simple Clinical Colitis Activity Index and faecal calprotectin.

Polyphenols modulate gut microbiota and promote the growth of lactobacilli and bifidobacteria. Gut microbiota changes may decrease gut inflammation.

Despite this, the overall evidence landscape for specific diets in UC remains early-stage: current research on dietary interventions primarily targets Crohn's disease, with a relatively scant focus on UC and generally low quality of evidence for the studies conducted. The limited evidence available lacks sufficient rigor and consistency to establish strong conclusions regarding the efficacy of specific dietary patterns or food groups in UC management. The heterogeneity in study designs, sample sizes, and intervention protocols further complicates the ability to draw reliable inferences.

10.3 Specific Carbohydrate Diet (SCD) and Low-FODMAP

Recent data suggest healthful dietary patterns alone, with an emphasis on whole foods that are high in vegetable fiber and that promote less consumption of ultra-processed foods, may also help achieve remission in ulcerative colitis and Crohn's disease patients. The Specific Carbohydrate Diet and the Mediterranean diet both help induce clinical remission in patients with Crohn's disease. Diets low in animal protein and high in fiber help induce and maintain remission in patients with ulcerative colitis and Crohn's disease and may improve quality of life. A low-FODMAP diet is restrictive but can help in patients with persistent IBS symptoms in the setting of quiescent IBD.

10.4 Dietary Fiber

Dietary fiber and vitamins found in fruits and vegetables assist in maintaining the intestinal mucosal barrier and balancing the intestinal inflammatory response, both of which are advantageous for people with IBD. The relationship between fiber and colitis is nuanced — type, quantity, and fermentability of fiber may produce different outcomes. There are signals that a Mediterranean diet pattern reduces the risk of Crohn's disease but, again, the data are inconsistent and further studies are much needed. Further research is needed to clarify the optimal diet for those at risk of ulcerative colitis.

10.5 Physical Activity

Physical activity improves quality of life without detrimental effect on disease activity, and may contribute to increase muscle mass and to prevent osteoporosis in patients with IBD including colitis. The existing evidence on physical activity in colitis is generally positive for quality of life outcomes, though large-scale intervention trials on disease activity endpoints remain limited.

11. Summary of Evidence Strength

Probiotics in UC: Moderate-quality evidence from RCTs and systematic reviews suggesting benefit as an adjunct to conventional treatment for induction of remission; evidence is weaker for Crohn's colitis. Strain, dose, and patient-population specificity are not yet established.
Curcumin (adjunct in UC): Multiple RCTs and meta-analyses show statistically significant improvements in clinical and endoscopic outcomes as an adjunct to conventional therapy, but the underlying systematic reviews are rated very low to moderate quality. Further high-quality trials are required.
Vitamin D: Strong observational and prospective epidemiological data link deficiency to worse disease outcomes; intervention RCTs show serum level improvement, but the clinical impact on disease activity requires larger, better-designed trials.
Omega-3 Fatty Acids: Epidemiological support and mechanistic plausibility; clinical trial data are heterogeneous and inconclusive for induction or maintenance of remission in UC.
Mediterranean Diet: Promising from epidemiological and one small RCT; current evidence is preliminary and primarily observational.
Aloe Vera: Limited controlled trial evidence; primarily in vitro and animal data; one small RCT suggests tolerability and some benefit but findings need replication.
Boswellia serrata: Preliminary small-trial data and pre-clinical evidence; insufficient basis for clinical recommendation at this time.
Slippery Elm, Devil's Claw, Tormentil, Fenugreek: Traditional use documented; clinical trial evidence in humans with colitis is sparse or absent. Evidence currently does not extend beyond empirical use.
Dietary Fiber and SCFAs: Strong mechanistic and epidemiological evidence; clinical intervention data in UC are promising but not yet definitive.

References

Natural Remedies

Remedy 1

Probiotic-Rich Fermented Foods: Probiotics are living microorganisms that promote the growth of beneficial bacteria in the digestive tract, helping support digestion and immunity. Incorporate naturally fermented foods like plain yogurt with live cultures, kefir, sauerkraut, or kimchi into your daily diet to help restore a healthy gut microbiome.

Remedy 2

Turmeric (Curcumin): Curcumin, the active compound in turmeric root, has been studied for its anti-inflammatory properties and may help reduce inflammation in the colon and support a more balanced gut microbiome. Add turmeric to soups, stews, and smoothies, or take it as a standardized curcumin supplement — pairing it with black pepper (piperine) improves absorption.

Remedy 3

Slippery Elm Bark: Slippery elm becomes a soothing, mucilaginous gel when mixed with water, which is thought to coat and protect the lining of the colon and reduce irritation. Mix one tablespoon of powdered slippery elm bark into a glass of warm water and drink it before meals or at the onset of symptoms.

Remedy 4

Aloe Vera Juice: Aloe vera contains polysaccharides and antioxidant compounds that may help reduce inflammation and support healing of inflamed intestinal tissues. Drink a small amount (about 2–4 oz) of pure, additive-free aloe vera juice daily, ideally diluted with water — use food-grade inner-leaf gel products and consume in moderation.

Remedy 5

Omega-3 Fatty Acids (Fish Oil): Omega-3 fatty acids, found in oily fish like salmon and sardines and also available as fish oil supplements, may help reduce intestinal inflammation and support remission. Aim to eat fatty fish two to three times per week, or take a daily fish oil supplement as an anti-inflammatory dietary measure.

Remedy 6

Low-Residue / Easily Digestible Diet: During flare-ups, shifting to a low-residue diet — focusing on well-cooked vegetables, white rice, bananas, plain chicken, and soft fruits — reduces the mechanical workload on an inflamed colon and can ease cramping and diarrhea. Keep a food journal to identify personal trigger foods such as raw vegetables, high-fiber grains, dairy, or added sugars, and eliminate them systematically.

Remedy 7

Wheatgrass Juice: Wheatgrass is rich in antioxidants and has been traditionally used to help ease pain, reduce inflammation, and support tissue repair in the gut. Drink a small shot (1–2 oz) of fresh or commercially prepared wheatgrass juice daily, or blend wheatgrass powder into a smoothie.

Remedy 8

Stress Management (Mindfulness & Breathwork): Colitis is strongly influenced by the gut-brain axis, with chronic psychological stress elevating cortisol and pro-inflammatory cytokines that worsen symptoms and increase flare risk. Practice daily mindfulness meditation, deep diaphragmatic breathing, or yoga for at least 10–15 minutes to shift the nervous system into a rest-and-digest state and lower the gut's inflammatory burden.

Remedy 9

Gentle, Consistent Exercise: Moderate physical activity such as walking, swimming, or yoga supports circulation, mood regulation, immune function, and healthy digestion in people with colitis. Aim for 20–30 minutes of low-impact movement most days, and scale back to gentle stretching or slow walks during active flares to avoid overexerting an already stressed system.

Remedy 10

Sleep Hygiene & Consistent Rest Schedule: Poor or insufficient sleep can increase inflammatory cytokines and contribute to worsening disease activity in colitis. Establish a consistent bedtime and wake schedule, keep the bedroom dark, cool, and quiet, and avoid large meals or excessive fluids close to bedtime to minimize nocturnal digestive symptoms and support overnight tissue repair.

Ingredients

These ingredients are often used in alternative medicine to support colitis.

2'-fucosyllactoseScientific
Multiple preclinical studies in DSS-induced colitis mouse models consistently show that 2'-FL reduces disease activity index scores, attenuates colon shortening, suppresses pro-inflammatory cytokines (IL-6, TNF-α), and restores gut microbiota composition. A key mechanism involves restoration of goblet cells, increased MUC2 secretion, and inhibition of TLR4/NF-κB and STAT3 pathways. An open-label pilot clinical trial in 12 adults with ulcerative colitis showed improved gastrointestinal quality-of-life scores and increased butyrate-producing bacteria after 6 weeks of a 2'-FL-containing formula.
acemannanScientific
Acemannan has been investigated in a pilot clinical study for inflammatory bowel disease including ulcerative colitis, with all participants showing score improvements. Aloe vera gel (the major vehicle of acemannan) showed benefit in a double-blind, placebo-controlled trial for active ulcerative colitis. Mechanistic support comes from rodent models of colitis.
aloe veraScientific
A double-blind, placebo-controlled RCT demonstrated that oral aloe vera gel (100 ml twice daily for 4 weeks) induced clinical remission in active ulcerative colitis patients, outperforming placebo. In vitro studies show aloe gel reduces prostaglandin E2 and IL-18 secretion in colonic mucosa, supporting anti-inflammatory activity.
andrographisScientific
Andrographis paniculata extract (standardized for andrographolide) has been tested in randomized controlled trials for mild-to-moderate active ulcerative colitis, showing remission and response rates comparable to mesalazine. It is also used in Ayurvedic and traditional Chinese medicine for gastrointestinal inflammatory conditions.
andrographolideScientific
Andrographolide, the primary active compound of Andrographis paniculata, has been evaluated in clinical trials for mild-to-moderate active ulcerative colitis. A randomized trial in 120 UC patients found it produced clinical remission and response rates comparable to mesalazine. It inhibits NF-κB and reduces pro-inflammatory cytokines.
assam indigoScientific
Multiple human clinical trials of Qingdai (derived from S. cusia) have demonstrated efficacy in ulcerative colitis, including mucosal healing and remission induction. Mechanistic studies show action via the AHR-Th17/Treg pathway and IL-17 inhibition by S. cusia-derived alkaloids.
bacillus coagulansScientific
B. coagulans has been evaluated in IBD populations including ulcerative colitis, with evidence of anti-inflammatory effects and symptom improvement. The organism reduces pro-inflammatory cytokines and abdominal symptoms in inflamed bowel conditions. Evidence is preliminary but grounded in clinical trials.
bee pollenScientific
Buckwheat and apricot bee pollen extracts reduced DSS-induced ulcerative colitis severity in mouse models, modulating Th1/Th2 cytokine balance, reducing ICAM-1 expression, and improving gut microbiota composition. The anti-inflammatory and microbiota-modulating mechanisms are well-characterized at the preclinical level.
berberineScientific
A 2024 meta-analysis of 10 RCTs (952 UC patients) found berberine combined with 5-ASA significantly improved clinical efficacy rate (RR=1.22), reduced disease activity index scores, and attenuated inflammatory markers. Berberine has been used in traditional Chinese medicine for centuries for gastrointestinal inflammatory conditions.
bifidobacteriumScientific
Bifidobacterium species are among the most studied probiotics for ulcerative colitis. Systematic reviews of RCTs confirm that Bifidobacteria-containing probiotics have positive effects in treatment and maintenance of UC. B. longum, B. breve, B. animalis subsp. lactis, and B. bifidum are among the most studied strains.
bifidobacterium bifidumScientific
Bifidobacterium bifidum is included in multi-strain probiotic formulations (including VSL#3 predecessor formulations) that have demonstrated benefit for ulcerative colitis and pouchitis in RCTs. Systematic reviews confirm Bifidobacteria including B. bifidum contribute to UC treatment and maintenance of remission.
bifidobacterium breveScientific
Bifidobacterium breve is a component of VSL#3 and other multi-strain probiotic formulations that have demonstrated benefit for UC and pouchitis in randomized controlled trials. Systematic reviews of probiotic RCTs in IBD confirm positive effects of Bifidobacteria-containing probiotics in UC treatment and maintenance.
bifidobacterium lactisScientific
Bifidobacterium lactis (animalis subsp. lactis) has been specifically tested in a randomized, double-blind, placebo-controlled trial for collagenous colitis in combination with Lactobacillus acidophilus. It is among the most widely used Bifidobacteria strains in IBD probiotic research and multi-strain formulations for UC.
bifidobacterium longumScientific
Bifidobacterium longum BB536 has been specifically identified in clinical studies as beneficial for UC symptom management. It is among the most frequently studied Bifidobacterium strains for UC alongside L. rhamnosus GG. VSL#3 probiotic mixture containing B. longum showed benefit in pouchitis RCTs.
bilberryScientific
An open prospective pilot trial in 13 UC patients treated with anthocyanin-rich bilberry for 6 weeks achieved remission in 63.4% and response in 90.9%, with significant reductions in endoscopic and biochemical disease activity. A follow-up molecular study confirmed reduced IFN-γ and TNF-α in colon biopsies of responders. Evidence is preliminary but is the first human data.
black cuminScientific
Ulcerative colitis patients were included in a meta-analysis (7 RCTs) showing significant CRP reductions with N. sativa supplementation. Animal models confirm TQ's anti-colitic effects via NF-κB inhibition. The PMC GI review documents clinical and experimental evidence for N. sativa's effects on colitis.
boswelliaScientific
Boswellia serrata gum resin extract has been tested in small clinical trials for ulcerative colitis and collagenous colitis. In one study of 20 UC patients receiving 300 mg three times daily for 6 weeks, 14 achieved remission, compared to only 4/10 in the sulfasalazine group. Boswellic acids inhibit 5-lipoxygenase, reducing leukotriene synthesis.
boswellic acidScientific
Boswellic acids are the active constituents of Boswellia serrata responsible for anti-inflammatory effects in ulcerative and collagenous colitis. They inhibit 5-lipoxygenase and NF-κB, reducing pro-inflammatory leukotriene and cytokine production. Small clinical trials have demonstrated remission rates comparable to or exceeding sulfasalazine in UC patients.
bromelainScientific
Multiple preclinical and emerging clinical studies demonstrate bromelain's potential in ulcerative colitis, including an animal model showing markedly decreased IBD development and severity, and anecdotal reports of remission in two UC patients. A 2025 randomized triple-blind placebo-controlled RCT in 70 UC patients evaluated bromelain on disease activity and quality of life over 8 weeks.
butyrate triglycerideScientific
Tributyrin has direct evidence in experimental colitis models, showing antioxidative and immunomodulatory effects, and reduced colonic mucosal lesions and inflammation when given orally or as an enema. Butyrate enemas were evaluated in human ulcerative colitis trials from 1992 onward with positive but mixed outcomes. Animal models consistently support tributyrin's protection against DSS-induced colitis through barrier repair and cytokine suppression.
butyric acidScientific
Butyric acid (butyrate) is the primary energy substrate for colonocytes and has been investigated as a treatment for ulcerative colitis. Butyrate enemas have been tested in RCTs for distal UC, showing improvement in histological and clinical scores. It inhibits NF-κB, promotes colonocyte proliferation, and supports tight junction integrity.
cabbageScientific
Red cabbage juice has been shown in animal models of DSS-induced colitis to significantly reduce disease activity, improve colonic barrier integrity by upregulating tight junction proteins, and enrich SCFA-producing bacteria. A mouse study (PMC10778654, 2023) demonstrated that red cabbage juice modulated gut microbiota and ameliorated experimental colitis. Red cabbage extract has also attenuated experimental IBD in mouse models in vitro.
caryophylleneScientific
BCP has been shown to inhibit dextran sulfate sodium (DSS)-induced colitis in mice through CB2 receptor activation and the PPARγ pathway, reducing disease activity, colonic damage, and pro-inflammatory cytokines. This is among the most robust preclinical findings for BCP.
chlorellaScientific
A pilot RCT at Virginia Commonwealth University included 9 ulcerative colitis patients treated with chlorella and assessed disease activity. A 2008 open-label study also observed digestive symptom improvements in patients with IBS and ulcerative colitis.
coptis chinensisScientific
Coptis chinensis and berberine have demonstrated anti-colitis effects in multiple animal models of ulcerative colitis, reducing inflammatory infiltration, restoring gut microbiota balance, and reinforcing the intestinal barrier. Clinical evidence supports berberine use in gastritis and enteritis, and TCM historically used the herb for dysentery symptoms resembling UC.
curcuminScientific
Multiple RCTs and systematic reviews support curcumin as adjunctive therapy for ulcerative colitis (UC). A 2024 meta-analysis of 8 RCTs (482 patients) found adjunctive curcumin significantly improved clinical remission (RR=2.33, 95% CI: 1.25–4.34). It works via NF-κB inhibition and blockade of TNF-α binding, reducing mucosal inflammation.
DPA (docosapentaenoic acid)Scientific
In a mouse model of DSS-induced ulcerative colitis, DPA supplementation alleviated colitis severity by modifying gut microbiota composition and fecal metabolite profiles. Beneficial genera including Akkermansia and Lactobacillus were enriched, and butyrate production was increased. Evidence is currently limited to preclinical animal models.
EPA (eicosapentaenoic acid)Scientific
EPA as a free fatty acid (EPA-FFA) has been tested in placebo-controlled trials in ulcerative colitis (UC) with positive results. A 60-patient RCT found 6 months of EPA-FFA reduced fecal calprotectin (a marker of mucosal inflammation) and prevented relapse. Mendelian randomization data also indicate higher genetically predicted EPA concentrations associate with reduced IBD risk.
fish oilScientific
Fish oil (omega-3 fatty acids) has been evaluated in multiple RCTs and two Cochrane reviews for ulcerative colitis. While individual small trials show anti-inflammatory benefit and reduced steroid requirements, Cochrane reviews found insufficient definitive evidence for maintenance of remission. Fish oil reduces leukotriene B4 and pro-inflammatory eicosanoid production in colonic mucosa.
FOS (fructooligosaccharides)Scientific
Fructooligosaccharides (FOS) are prebiotic fibers that selectively feed beneficial colonic bacteria, promote butyrate production, and have been studied in combination with probiotics (synbiotics) for IBD including UC. Synbiotics containing FOS showed clearer effectiveness in Crohn's disease and positive effects in UC in systematic reviews.
fulvic acidScientific
In vivo rat studies show shilajit (containing fulvic acid) reduced intestinal damage and inflammatory markers in chemically induced colitis. Fulvic acid's anti-inflammatory mechanisms (TNF-α and COX-2 suppression) are mechanistically relevant to colitis pathology.
gardeniaScientific
Gardenia jasminoides fruit extract (GFE) and its constituent geniposide have demonstrated protective effects in multiple rat models of ulcerative colitis (TNBS- and DSS-induced). GFE significantly reduced disease activity index scores, histological damage, and pro-inflammatory cytokines while increasing antioxidant capacity. Geniposide's mechanism involves KEAP1-Nrf2 pathway activation and barrier function restoration.
gingerScientific
Ginger (Zingiber officinale) has been investigated in a registered RCT for active ulcerative colitis; its bioactive compounds (shogaols, gingerols) have anti-inflammatory and antioxidant properties. A meta-analysis of polyphenols in UC confirmed ginger powder reduces clinical activity scores in UC patients.
green chirettaScientific
Green chiretta extract (HMPL-004) has been evaluated in two randomised, double-blind clinical trials in ulcerative colitis patients, with the 1,800 mg/day dose producing significantly higher clinical response rates versus placebo. One trial found efficacy comparable to mesalamine.
holarrhena antidysentericaScientific
A randomized single-blind clinical trial (PMC5255966) compared a monoherbal H. antidysenterica formulation to mesalamine in chronic ulcerative colitis patients, finding comparable or superior efficacy with fewer relapses. Animal studies using DNBS-induced colitis also support anti-colitic activity. This represents the strongest human clinical evidence for this herb.
honeysuckleScientific
Honeysuckle-derived nanovesicles reduced colitis symptoms, colonic inflammation, and histopathological damage, restored Treg/Th17 balance, and repaired intestinal barrier integrity in DSS-induced murine colitis. Honeysuckle MIR2911 was shown to reduce Escherichia-Shigella abundance and improve colitis via gut microbiota regulation. These are preclinical findings without human trial data.
immunoglobin GScientific
SBI has been studied in ulcerative colitis patients as an adjunct to standard regimens, with a pediatric case report documenting clinical and pathological remission. Preclinical mouse models show oral SBI attenuates DSS-induced colitis inflammation. An ex vivo human sample study confirmed SBI reduces key colonic inflammatory cytokines.
indian baelScientific
Bael unripe fruit extract demonstrated significant anti-colitic effects in both acetic acid-induced ulcerative colitis and indomethacin-induced enterocolitis rat models, with dose-dependent reduction in inflammation markers and protection of intestinal mast cells. Traditional Ayurvedic formulations containing bael specifically target colitis.
indian frankincenseScientific
Multiple clinical trials have examined Boswellia serrata in ulcerative colitis and chronic colitis. A key RCT showed 82% of Boswellia-treated patients entered remission — a result comparable to sulfasalazine. Additional trials confirmed improvements in stool properties, histopathology, and haematological parameters at 350 mg three times daily for 6 weeks.
indigo leavesScientific
Indigo naturalis (derived from indigo plant leaves) has the strongest clinical evidence base in ulcerative colitis of any traditional herbal medicine. Multiple RCTs and a comprehensive PMC systematic review confirm efficacy in inducing clinical response and mucosal healing in active UC. The mechanism involves aryl hydrocarbon receptor (AhR) activation and IL-22 induction.
inulinScientific
Inulin-type beta-fructan prebiotics have been tested in a double-blind, placebo-controlled RCT for prevention of UC relapse. While the trial did not prevent clinical relapse, it significantly reduced the risk of subclinical relapse defined by elevated fecal calprotectin. Inulin promotes beneficial microbiota and butyrate production in the colon.
jujubeScientific
Jujube polysaccharides and hydroalcoholic extracts have demonstrated efficacy in multiple colitis animal models, reducing pro-inflammatory cytokines, improving mucosal damage, and modulating gut microbiota. Evidence includes acetic acid–induced UC in mice, DSS-induced colitis, and TNBS-induced IBD in rats. All current evidence is preclinical.
L-alanyl-L-glutamineScientific
Multiple animal studies using DSS- and TNBS-induced colitis models show AG reduces colitis severity, shortens colon damage, suppresses inflammatory cytokines, and modulates gut microbiota. AG outperformed free glutamine in alleviating DSS-colitis in mice. Human clinical data are primarily derived from IBD/surgical populations where glutamine as AG is part of nutritional support.
L-glutamineScientific
L-glutamine is the primary fuel for rapidly dividing intestinal enterocytes and has been investigated in preclinical colitis models. A 2018 study showed L-glutamine attenuates DSS-induced colitis in mice via MAPK phosphatase-1 induction. It is listed among other proposed natural treatments for UC including phosphatidylcholine, curcumin, and bromelain.
lactobacillusScientific
Lactobacillus species (particularly L. rhamnosus GG, L. plantarum, L. acidophilus, L. casei) have been investigated in numerous RCTs for ulcerative colitis. Systematic reviews confirm that probiotics including Lactobacillus have positive effects in treatment and maintenance of UC. They modulate gut microbiota, reduce mucosal inflammation, and strengthen the intestinal barrier.
lactobacillus acidophilusScientific
Lactobacillus acidophilus has been investigated in RCTs for ulcerative colitis and collagenous colitis, and is among the most commonly used probiotic strains for IBD. A double-blind, placebo-controlled RCT specifically tested L. acidophilus with Bifidobacterium animalis subsp. lactis for collagenous colitis. It modulates gut microbiota and mucosal immune responses.
lactobacillus bulgaricusScientific
L. bulgaricus is a component of VSL#3, which has been studied in multiple RCTs for ulcerative colitis and shown to induce remission. L. bulgaricus alone has been shown in animal models (azoxymethane/DSS mouse model) to attenuate intestinal inflammation and reduce pro-inflammatory cytokines (IL-6, TNF-α, IL-17, IL-23, IL-1β). Human-level evidence is primarily from multi-strain formulations that include L. bulgaricus.
lactobacillus caseiScientific
Lactobacillus casei is among the Lactobacillus strains investigated in multi-strain probiotic trials for ulcerative colitis. It is included in multi-strain synbiotic formulations demonstrating anti-pathogenic and gut microbiota-modulating activity relevant to colitis management.
lactobacillus paracaseiScientific
L. paracasei E10 significantly alleviated colitis symptoms in a dextran sulfate sodium (DSS) mouse model by reducing disease activity index, preserving colonic architecture, increasing goblet cell density, and upregulating tight junction proteins. A clinical trial (NCT07017959) is currently investigating L. paracasei D3.5 for IBD in adults, though published human RCT data are limited.
lactobacillus plantarumScientific
Lactobacillus plantarum has been studied in RCTs for ulcerative colitis, and is included in multi-strain probiotic formulations with demonstrated benefit in IBD. It improves intestinal barrier function, modulates colonic microbiota, and reduces pro-inflammatory cytokines in UC patients.
lactobacillus rhamnosusScientific
Lactobacillus rhamnosus GG (LGG) is among the most extensively studied probiotics for ulcerative colitis, with documented mucosal adhesion capacity, anti-inflammatory activity, and a favorable safety profile across clinical trials. It has been evaluated as monotherapy in mild-to-moderate UC, and is commonly studied in combination with Bifidobacterium.
lactobacillus salivariusScientific
L. salivarius UCC118 has demonstrated anti-colitic activity in a DSS-induced mouse colitis model, accelerating recovery through upregulation of IL-10, M2 macrophage polarization, and restoration of gut microbial diversity. Human IBD-specific RCT data for L. salivarius specifically remain limited, though its immunomodulatory mechanisms are directly relevant to colitis pathophysiology.
lactococcus lactisScientific
Multiple preclinical studies demonstrate that L. lactis — both wild-type and GM strains — attenuates experimental colitis by reducing inflammatory cytokines, preserving tight junction integrity, and modulating the colonic immune environment. Heat-killed L. lactis L8 reduced TNF-α and clinical colitis scores in DSS-induced murine colitis. GM L. lactis secreting IL-10 and IL-1Ra have also shown efficacy in rodent colitis models and have proceeded to human clinical safety trials.
lactoferrinScientific
Fecal lactoferrin is a validated biomarker for colitis disease activity in both ulcerative colitis and Crohn's disease. As a therapeutic, lactoferrin shows immunomodulatory potential for IBD/colitis contexts via mucosal immune regulation, though direct treatment RCT data in colitis is limited primarily to case reports and biomarker studies.
lecithinScientific
Phosphatidylcholine (the active component of lecithin) is deficient in the colonic mucus of ulcerative colitis patients, and multiple RCTs show that delayed-release PC preparations significantly improve remission rates and reduce steroid dependence. A meta-analysis of three RCTs confirmed significant clinical, endoscopic, and histological improvements. Evidence is specifically for ulcerative colitis, not Crohn's disease.
limoneneScientific
D-limonene has been specifically studied in ulcerative colitis rat models, demonstrating significant reductions in disease activity, colonic mucosa damage, and inflammatory markers (MMP-2, MMP-9, COX-2, PGE2, TGF-β). At 50–100 mg/kg, it produced measurable anti-inflammatory and antioxidant effects in the inflamed colon. Evidence is preclinical (rodent models); no human UC clinical trials have been conducted.
mastic gumScientific
Both animal and preliminary human data support mastic gum's activity against colitis. Key constituents reduce NF-κB, TNF-α, IL-6, and IL-8, and improve gut barrier integrity. A 2022 study showed masticadienonic acid mitigated DSS-induced colitis in mice through microbiota modulation and tight junction upregulation. Small human RCT data adjunct to standard IBD therapy showed reduced disease activity markers.
milk thistleScientific
Milk thistle (Silybum marianum), through its active complex silymarin, has shown positive results in a small placebo-controlled clinical trial in ulcerative colitis patients. Silymarin suppresses NF-κB-mediated inflammation and reduces TNF-α and IL-1β in bowel tissue. A registered clinical trial is ongoing to confirm its efficacy as adjunct therapy in UC.
mucinScientific
Mucin barrier defects—particularly altered MUC2 expression and goblet cell dysfunction—are well-documented in both ulcerative colitis (UC) and Crohn's disease in human biopsy studies. Muc2-deficient mice spontaneously develop colitis, establishing a causal mechanistic link. Clinical studies show that mucin expression profiles are abnormal in UC at disease onset and after treatment.
myrrhScientific
The myrrh-containing combination product Myrrhinil-Intest demonstrated noninferiority to mesalazine in maintaining remission in ulcerative colitis in a double-blind RCT. Animal models of acetic acid–induced colitis show myrrh reduces colon weight, inflammatory cell infiltration, and mucosal damage while upregulating antioxidant defenses.
N-acetyl-glucosamineScientific
NAG has direct clinical evidence in inflammatory bowel disease including ulcerative colitis. A pediatric pilot trial (Salvatore et al., Alimentary Pharmacology & Therapeutics, 2000) and animal studies in DSS-induced colitis (Food & Function, 2023) both show histological and clinical improvements with NAG administration. NAG replenishes intestinal mucosa glycosaminoglycans that are depleted in colitis.
NAC (N-acetyl cysteine)Scientific
N-acetyl cysteine (NAC) has been investigated in experimental colitis models and mentioned in reviews as potentially controlling and preventing ulcerative colitis. It serves as a glutathione precursor, reducing oxidative stress in inflamed colonic mucosa. A study demonstrated molecular evidence for its benefits in experimental colitis.
oleanolic acidScientific
OA ameliorates dextran sodium sulfate (DSS)-induced colitis in mice by restoring Th17/Treg balance, inhibiting NF-κB, preserving intestinal tight junction proteins (ZO-1, occludin), and reducing inflammatory cytokines. Multiple independent murine studies confirm these effects.
omega-3 fatty acidsScientific
Omega-3 fatty acids have been evaluated in multiple RCTs and Cochrane reviews for UC and Crohn's disease. They reduce leukotriene B4 and pro-inflammatory eicosanoid production in colonic mucosa. IOIBD dietary guidance recommends increased omega-3 consumption from natural food sources for UC patients, though supplement evidence for remission maintenance is inconclusive.
phosphatidylcholineScientific
The colonic mucus layer is normally enriched in PC, and patients with ulcerative colitis show significantly depleted mucosal PC. Multiple RCTs demonstrate that delayed-release PC supplementation reduces disease activity, induces remission, and supports steroid withdrawal in active UC. This is one of the best-evidenced therapeutic applications of PC.
plantagoScientific
A landmark RCT demonstrated Plantago ovata seeds (dietary fiber) were as effective as mesalamine in maintaining remission in ulcerative colitis. Psyllium's prebiotic fermentation raises colonic butyrate, supporting mucosal integrity. Clinical evidence is strongest for ulcerative colitis maintenance.
plantainScientific
A randomized clinical trial found Plantago ovata seeds equivalent to mesalamine for UC remission maintenance. Psyllium fiber specifically protected against experimental colitis in mouse models where other fibers worsened disease. A case report documented improvement in refractory ulcerative pancolitis with P. major. The protective mechanism involves SCFA production and intestinal barrier maintenance.
pomegranateScientific
Pomegranate (Punica granatum) and its rich ellagitannins (punicalagins, ellagic acid) have demonstrated anti-UC effects in numerous preclinical investigations and clinical human trial reports. A double-blind RCT evaluated pomegranate juice for reducing fecal calprotectin in IBD patients. An ongoing UCLA trial is studying pomegranate juice effects on UC inflammation and gut microbiota.
prickly pear cactusScientific
An animal/cell study found prickly pear (O. dillenii) juice protected against ulcerative colitis-induced colon damage via phenolics, flavonoids, and betalains. In vitro studies on human intestinal cells confirm anti-inflammatory effects on intestinal epithelial inflammation. Human clinical trials are lacking.
psylliumScientific
Psyllium (Plantago ovata husk) has been evaluated in clinical trials for UC maintenance and shown efficacy comparable to mesalazine for maintenance of remission in mild-to-moderate UC in at least one RCT. It acts as a prebiotic fiber, increasing butyrate-producing bacteria and fecal butyrate levels in UC patients.
quercetinScientific
Quercetin, a flavonoid with potent anti-inflammatory and antioxidant properties, has been investigated in preclinical and clinical contexts for ulcerative colitis. It modulates NF-κB, reshapes gut microbiota, and restores tryptophan metabolism to support intestinal barrier integrity. It is included in polyphenol meta-analyses showing benefit in UC.
resveratrolScientific
Resveratrol, a polyphenol stilbene, has been tested in RCTs for ulcerative colitis. A meta-analysis of polyphenol RCTs confirmed resveratrol-containing preparations reduced clinical activity in UC and improved remission rates. It inhibits NF-κB and NLRP3 inflammasome activation in the colonic mucosa.
saccharomyces boulardiiScientific
Saccharomyces boulardii has been evaluated in a pilot trial for ulcerative colitis and in animal models of DSS-induced colitis, showing modulation of NF-κB and Nrf2 signaling. It has well-established evidence for C. difficile-associated colitis and antibiotic-associated colitis. Anti-inflammatory mechanisms in UC have been described.
silymarinScientific
Silymarin, the flavonolignan complex from milk thistle (Silybum marianum), showed positive results in a small randomized, double-blind, placebo-controlled clinical trial in UC patients. It suppresses NF-κB, reduces TNF-α and IL-1β in colonic tissue, and an ongoing registered RCT (NCT06213857) is further evaluating its efficacy in UC.
sophoraScientific
Oxymatrine from S. flavescens is commonly used in China to treat ulcerative colitis, with multiple licensed formulations. A 2025 systematic review and meta-analysis of 12 preclinical studies confirmed oxymatrine's efficacy in IBD models. Human RCT meta-analyses of Five-Flavor Sophora Enteric-Coated Capsules (containing S. flavescens) for UC have been published.
SPMs (specialized pro-resolving mediators)Scientific
Serum maresin-1 and resolvin D1 are established disease activity biomarkers in ulcerative colitis patients. Ex vivo studies using intestinal biopsies from Crohn's disease patients show resolvin D2 reduces mucosal cytokine production. SPMs have been tested in preclinical colitis models with consistent efficacy.
stigmasterolScientific
Stigmasterol significantly attenuated experimental colitis in DSS-induced mouse models by restoring Treg/Th17 immune balance via the butyrate-PPARγ axis and modulating gut microbiota composition. Fecal microbiota transplant experiments confirmed microbiota-mediated anti-inflammatory effects.
streptococcus thermophilusScientific
S. thermophilus is one of the eight strains in VSL#3, a probiotic preparation with the strongest evidence base for ulcerative colitis, including induction of remission in mild-to-moderate disease in randomized controlled trials. Animal studies with specific S. thermophilus strains also demonstrate delayed colitis onset and improved mucosal barrier function.
sulforaphaneScientific
Sulforaphane reduces colonic inflammation in DSS-induced colitis models via Nrf2 activation, NF-κB suppression, restoration of tight junction proteins, and gut microbiome remodeling. Pretreatment with SFN significantly improved inflammatory biomarkers and symptoms in murine colitis models.
sweet wormwoodScientific
Artemisinin and artesunate, derivatives of A. annua, have shown significant anti-colitis activity in DSS and TNBS rodent models, reducing colonic inflammation, macroscopic injury, and cytokine levels. A 2025 review in Acta Pharmacologica Sinica summarizes the multi-target therapeutic rationale for artemisinins in colitis.
tributyrinScientific
Multiple animal models show tributyrin reduces inflammation and supports mucosal repair in colitis, acting via NF-κB inhibition, Treg promotion, and cytokine modulation. Butyrate supplementation RCTs in ulcerative colitis patients (not tributyrin-specific) show reductions in disease severity scores and inflammatory markers. Human evidence specific to tributyrin in colitis remains limited to pilot data.
turmericScientific
Multiple RCTs and a 2024 meta-analysis of 13 placebo-controlled trials demonstrate curcumin's efficacy as an adjunctive therapy for ulcerative colitis, improving clinical remission rates and clinical response. Curcumin is extensively studied in IBD and has a substantial evidence base for UC specifically. Typical use is as adjunct to mesalamine.
vitamin DScientific
Vitamin D supplementation has been tested in a randomized clinical trial in UC patients with vitamin D deficiency (hypovitaminosis D), showing increased vitamin D levels over 90 days. Systematic reviews support vitamin D's role in intestinal barrier integrity, VDR-mediated anti-inflammatory signaling, and promoting butyrate-producing commensal bacteria in UC.
vitamin D3Scientific
Vitamin D3 (cholecalciferol) has been specifically tested in a double-blind RCT in UC patients with vitamin D deficiency, showing increased serum levels and improvements in quality of life and disease activity indices at doses of 2,000–4,000 IU/day over 90 days. VDR-mediated signaling supports intestinal barrier integrity and reduces colonic inflammation.
wheatScientific
Wheat bran polyphenols reduced DSS-induced colitis severity in animal models by suppressing MAPK/NF-κB inflammatory signaling and modulating gut microbiota. Wheat arabinoxylan may prevent colitis by increasing colonic regulatory T cells. Human clinical evidence is indirect (low-fiber wheat products served as the control arm in oat bran UC trials), with direct wheat-specific colitis RCTs lacking.
wheat grassScientific
Wheatgrass juice was tested in a randomized, double-blind, placebo-controlled trial in 23 active distal UC patients; those receiving 100 ml/day for one month showed significant reductions in disease activity and rectal bleeding compared to placebo. A polyphenol meta-analysis for UC confirmed wheatgrass juice improved clinical activity scores.
xylooligosaccharidesScientific
In vitro fermentation studies with fecal samples from UC patients in remission show XOS significantly enriches Bifidobacterium and butyrate-producing Roseburia, bacteria known to reduce colitis severity. Animal models confirm XOS combined with Bifidobacterium infantis alleviates dextran sulfate sodium-induced colitis. Human interventional trials in active colitis remain limited.
yellow rootScientific
Berberine, Yellow Root's active constituent, shows significant activity against experimental colitis in animal models and has been explored in a human clinical trial for ulcerative colitis. Yellow Root was traditionally used for bowel inflammation. Berberine inhibits inflammatory pathways relevant to colitis.
yuccaScientific
Yucca is traditionally and clinically cited for intestinal inflammation including colitis. Drugs.com and Rxlist list colitis as a recognized oral indication. Mechanistically, yucca saponins may modulate gut microbiota and reduce gut permeability, while phenolics inhibit NF-κB-driven mucosal inflammation. No large-scale colitis-specific RCT exists, but the association appears in multiple clinical reference sources.
bayberryTraditional
Bayberry is specifically listed in multiple herbal references for colitis, particularly mucous colitis (irritable bowel with mucus). Its astringent tannins reduce intestinal secretion and inflammation. WebMD/RxList include colitis among conditions for which bayberry is used traditionally. No clinical trial evidence exists.
calendulaTraditional
Calendula infusion is traditionally used in herbal medicine for chronic colitis and ulcerative colitis, attributed to its anti-inflammatory and mucosal-healing properties. An animal model study in dogs demonstrated benefit in acetic acid-induced ulcerative colitis. No human RCTs exist for this indication.
cat's clawTraditional
Cat's claw is traditionally used for colitis and inflammatory bowel conditions, and multiple authoritative sources, including RxList, list it among treatments for 'inflammation of the lower bowel (colitis).' Preclinical studies show reduction of intestinal inflammation markers. No randomized controlled trials in human colitis patients have been published.
chamomileTraditional
Chamomile has been used traditionally for gastrointestinal inflammation and is listed among botanical remedies for UC in evidence-based complementary therapy reviews. Its anti-inflammatory terpenoids (alpha-bisabolol) and flavonoids (apigenin) have demonstrated gut anti-inflammatory activity, and it has been included in clinical-study summaries for UC complementary care.
chickweedTraditional
Chickweed is used in herbal practice for colitis and inflammatory bowel conditions, leveraging its cooling, demulcent, and anti-inflammatory actions internally. Herbal Reality specifically lists colitis among digestive indications. No clinical evidence is available.
flowering quinceTraditional
C. speciosa is documented in TCM for enteritis, a category that includes colitis-like inflammatory bowel conditions. The fruit is listed in the Chinese Pharmacopeia and multiple pharmacological reviews for enteritis treatment. Preclinical anti-inflammatory data in gut-relevant models provides mechanistic support, though no studies specifically targeting colitis as an endpoint have been published.
goldensealTraditional
Goldenseal is traditionally indicated for intestinal inflammation, and berberine—its main alkaloid—has been examined in preclinical colitis models with promising results. Human clinical data for goldenseal itself in colitis are lacking, though berberine's anti-inflammatory mechanisms are well documented preclinically.
marshmallowTraditional
Marshmallow has been used in traditional European and Greco-Roman medicine for gastrointestinal inflammatory conditions including colitis. The demulcent mucilage is proposed to coat and protect the inflamed intestinal lining. Some in vitro and animal evidence supports anti-inflammatory effects in the gut, but human clinical trials for colitis are absent.
nopalTraditional
Nopal and related Opuntia cacti have traditional use for colitis and intestinal inflammation in Mexican and sub-Saharan ethnomedicine. Preclinical evidence from a rodent DNBS-induced colitis model (using Nopalea cochenillifera, a related Opuntia genus cactus) showed significant reductions in IL-1β, TNF-α, NF-κB activation, and macroscopic colon damage. A promising role in inflammatory bowel disease and colitis has been noted in reviews. No human clinical trials have been identified.
slippery elmTraditional
Slippery elm (Ulmus rubra) bark has been used traditionally by Native Americans to treat diarrhea and gastrointestinal tract diseases, including inflammatory bowel conditions. Its mucilage forms a protective coating on the gut lining, and preliminary research suggests antioxidant effects relevant to IBD, though formal RCT evidence is lacking.
slippery elm barkTraditional
Slippery elm bark has a well-documented Native American traditional use for gastrointestinal inflammatory conditions including colitis. Its mucilage forms a soothing coating on inflamed colonic mucosa. Preliminary research supports antioxidant effects relevant to IBD, but formal RCT data are absent.
squawvineTraditional
Squawvine is listed in Eclectic herbal tradition and folk medicine as indicated for catarrhal colitis. The tannin-based astringent action on inflamed mucous membranes provides a plausible traditional rationale. No clinical studies have been conducted.